Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. reports developments for a commercial pharmaceutical business that markets differentiated products primarily in oncology. Company updates focus on product sales, commercial execution, portfolio changes, and financial results for its single reportable segment, including activity tied to Rolvedon and other branded pharmaceutical assets.
Recent announcements also cover capital-structure and corporate governance matters, material agreements, shareholder-related processes, and completed portfolio transactions. Assertio has reported the sale of U.S. rights to several branded products, including INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP, while continuing to frame its commercial strategy around oncology-focused products.
Assertio Holdings reported Q3 2020 net product sales of $34.3 million, a 21.4% increase compared to the pro-forma Q2 2020. Non-GAAP sales were $33.7 million, maintaining consistency with the previous year despite COVID-19 disruptions. Demand for Zipsor increased by 25% quarter-over-quarter, while Indocin sales grew by 46% quarter-over-quarter. The company anticipates a 5% decline in full-year pro-forma revenue compared to 2019. Cash reserves declined to $34.7 million due to debt prepayments and restructuring costs. Assertio is focused on achieving $40 million in operational synergies from its merger.
Assertio Holdings, Inc. (Nasdaq: ASRT) will announce its Q3 2020 financial results on November 6, 2020. The management team will hold a live webcast at 8:30 a.m. ET to discuss the operating results and provide a business update. Assertio focuses on commercial pharmaceutical products in neurology, hospital, and pain management sectors. The company's growth strategy includes mergers and acquisitions, as well as licensing agreements. For more details, visit Assertio's website.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced participation in the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 2:00 pm ET. CEO Todd Smith will discuss Zyla Life Sciences integration, business strategy, financial results, and growth trends for the next year. The conference runs from September 15-17, 2020. Interested parties can find more details and listen to the webcast on Assertio's investor page. Assertio aims to be a leader in the pharmaceutical market, focusing on neurology, hospital, and pain management products.
Assertio Holdings reported its Q2 2020 financial results, highlighting a pro forma net product sales increase to $27.7 million compared to the previous quarter. The company successfully completed its merger with Zyla Life Sciences and fully integrated operations by the end of Q2. Assertio repaid $10 million of Senior Secured Notes ahead of schedule and projected mid-to-high single-digit growth for 2020. The cash position improved by over 40%, totaling $59.4 million at quarter-end, with a projected EBITDA margin exceeding 25%.
Assertio Holdings, Inc. (Nasdaq: ASRT) will release its Q2 2020 financial results on August 7, 2020. Following the announcement, management will host a live webcast at 8:30 a.m. ET to discuss the financials and provide a general business update. The webcast will be accessible on their investor relations website. Assertio focuses on bringing differentiated products to patients, with a strong portfolio in neurology, hospital care, and pain management.